|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes显示文摘This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further research in this understudied malignancy. Pancreatic adenocarcinoma is a lethal condition with a rising incidence, predicted to become the second leading cause of cancer death in some regions. It often presents at an advanced stage, which contributes to poor five-year survival rates of 2%-9%, ranking firmly last amongst all cancer sites in terms of prognostic outcomes for patients. Better understanding of the risk factors and symptoms associated with this disease is essential to inform both health professionals and the general population of potential preventive and/or early detection measures. The identification of high-risk patients who could benefit from screening to detect pre-malignant conditions such as pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms is urgently required, however an acceptable screening test has yet to be identified. The management of pancreatic adenocarcinoma is evolving, with the introduction of new surgical techniques and medical therapies such as laparoscopic techniques and neo-adjuvant chemoradiotherapy, however this has only led to modest improvements in outcomes. The identification of novel biomarkers is desirable to move towards a precision medicine era, where pancreatic cancer therapy can be tailored to the individual patient, while unnecessary treatments that have negative consequences on quality of life could be prevented for others. Research efforts must also focus on the development of new agents and delivery systems. Overall, considerable progress is required to reduce the burden associated with pancreatic cancer. Recent, renewed efforts to fund large consortia and research into pancreatic adenocarcinoma are welcomed, but further streams will be necessary to facilitate the momentum needed to bring breakthroughs seen for other cancer sites. | Andrew McGuigan Paul Kelly Richard C Turkington Claire Jones Helen G Coleman R Stephen McCain | 2018 | World Journal of Gastroenterology2018，24，43： | 140 |
| 2 | Achalasia: A review of clinical diagnosis, epidemiology,treatment and outcomes显示文摘Achalasia is a neurodegenerative motility disorder of the oesophagus resulting in deranged oesophageal peristalsis and loss of lower oesophageal sphincter function.Historically,annual achalasia incidence rates were believed to be low,approximately 0.5-1.2 per 100000.More recent reports suggest that annual incidence rates have risen to 1.6 per 100000 in some populations.The aetiology of achalasia is still unclear but is likely to be multi-factorial.Suggested causes include environmental or viral exposures resulting in inflammation of the oesophageal myenteric plexus,which elicits an autoimmune response.Risk of achalasia may be elevated in a sub-group of genetically susceptible people.Improvement in the diagnosis of achalasia,through the introduction of high resolution manometry with pressure topography plotting,has resulted in the development of a novel classification system for achalasia.This classification system can evaluate patient prognosis and predict responsiveness to treatment.There is currently much debate over whether pneumatic dilatation is a superior method compared to the Heller’s myotomy procedure in the treatment of achalasia.A recent com-parative study found equal efficacy,suggesting that patient preference and local expertise should guide the choice.Although achalasia is a relatively rare condition,it carries a risk of complications,including aspiration pneumonia and oesophageal cancer.The risk of both squamous cell carcinoma and adenocarcinoma of the oesophagus is believed to be significantly increased in patients with achalasia,however the absolute excess risk is small.Therefore,it is currently unknown whether a surveillance programme in achalasia patients would be effective or cost-effective. | Orla M O'Neill Brian T Johnston Helen G Coleman | 2013 | World Journal of Gastroenterology2013，19，35： | 26 |
| 3 | 染色体异常与男性不育显示文摘不育问题惊人地困扰着15%想要组建新家庭的人群。尽管如此,不育的分子遗传因素大多还不清楚。不过,越来越多不育遗传因素正逐渐被发现。本综述主要讨论目前了解的男性不育的染色体因素,尤其是染色体非整倍体、染色体组型的结构和数量异常和Y染色体微缺失。染色体非整倍体是人类流产和发育残疾的主要原因。非整倍体主要起源于母体,但是人们正在关注单精子注射的安全性,因为不育男性的精子非整倍体水平明显比起配偶高。染色体组型结构和数量异常的男性产生非整倍体精子的风险也越来越高。本文还综述了精子非整倍体如何被翻译至胚胎非整倍体,以及植入前基因诊断在这些病例中的应用。如果可能,文章还会做一下临床方面的建议,并讨论一些新兴的阵列技术在植入前基因诊断中使用以及在男性不育的潜在应用。 | Gary L Harton Helen G Tempest | 2012 | Asian Journal of Andrology2012，14，1： | 25 |
| 4 | Current practices and future prospects for the management of gallbladder polyps: A topical review显示文摘A gallbladder polyp is an elevation of the gallbladder mucosa that protrudes into the gallbladder lumen. Gallbladder polyps have an estimated prevalence in adults of between 0.3%-12.3%. However, only 5% of polyps are considered to be 'true' gallbladder polyps, meaning that they are malignant or have malignant potential. The main radiological modality used for diagnosing and surveilling gallbladder polyps is transabdominal ultrasonography. However, evidence shows that other modalities such as endoscopic ultrasound may improve diagnostic accuracy. These are discussed in turn during the course of this review. Current guidelines recommend cholecystectomy for gallbladder polyps sized 10 mm and greater, although this threshold is lowered when other risk factors are identified. The evidence behind this practice is relatively low quality. This review identifies current gaps in the available evidence and highlights the necessity for further research to enable better decision making regarding which patients should undergo cholecystectomy, and/or radiological follow-up. | R Stephen McCain Anna Diamond Claire Jones Helen G Coleman | 2018 | World Journal of Gastroenterology2018，24，26： | 25 |
| 5 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | The Lancet . 2005 (9472)2005，，9472： | 6 |
| 6 | Vleiotic recombination and male infertility: from basic science to clinical reality?显示文摘 | Michael Chann Patricio E Lau Helen G Tempest | 2011 | Asian Journal of Andrology2011，13，2： | 6 |
| 7 | Favorable response to subcutaneous administration of infliximab in rats with experimental colitis显示文摘AIM: To investigate the influence of infliximab (Remicade)on experimental colitis produced by 2,4,6,trinitrobenzene sulfonic acid (TNBS) in rats.METHODS: Thirty-six Wistar rats were allocated into four groups (three groups of six animals each and a fourth of 12 animals). Six more healthy animals served as normal controls (Group 5). Group 1:colitis was induced by intracolonic installation of 25 mg of TNBS dissolved in 0.25 mL of 50% ethanol and infliximab was subcutaneously administered at a dose of 5 mg/kg BW; Group 2: colitis was induced and infliximab was subcutaneously administered at a dose of 10 mg/kg BW; Group 3: colitis was induced and infliximab was subcutaneously administered at a dose of 15 mg/kg BW; Group 4: colitis was induced without treatment with infliximab. Infliximab was administered on d 2-6. On the 7th d, all animals were killed. The colon was fixed in 10%buffered formalin and examined by light microscopy for the presence and activity of colitis and the extent of tissue damage. Tumor necrosis factor-alpha (TNF-α) and malondialdehyde (MDA) were also measured.RESULTS: Significant differences concerning the presence of reparable lesions and the extent of bowel mucosa without active inflammation in all groups of animals treated with infliximab compared with controls were found. Significant reduction of the tissue levels of TNF-α in all groups of treated animals as compared withthe untreated ones was found (0.47±0.44, 1.09±0.86,0.43±0.31 vs 18.73±10.53 respectively). Significant reduction in the tissue levels of MDA was noticed in group 1 as compared to group 4, as well as between groups 2 and 4.CONCLUSION: Subcutaneous administration of infliximab reduces the inflammatory activity as well as tissue TNF-α and MDA levels in chemical colitis in rats.Infliximab at a dose of 5 mg/kg BW achieves better histological results and produces higher reduction of the levels of TNF-α than at a dose of 10 mg/kg BW.Infliximab at a dose of 5 mg/kg BW produces higher reduction of tissue MDA levels than at a dose of 15 mg/kg BW. | John K Triantafillidis Apostolos E Papalois Aikaterini Parasi Emmanuel Anagnostakis Stavros Burnazos Aristofanis Gikas Emmanuel G Merikas Emmanuel Douzinas Maria Karagianni Helen Sotiriou | 2005 | World Journal of Gastroenterology2005，11，43： | 5 |
| 8 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | The Lancet2005，，9472： | 4 |
| 9 | Nat Genet:单基因突变导致过敏性皮炎的发生显示文摘最近,研究者们鉴定出了一类导致神经性皮炎发生的关键基因突变:CARDll。来自美国NIH过敏与传染病研究所的研究者们通过对四个没有血缘关系的患病家庭进行分析,发现了这一导致疾病产生的基因、 | Chi A Ma, Yuan Zhang, Michael A Weinreich, Jonathan J Lyons, Celeste G Nelson, Thomas DiMaggio, Kelly D Stone, Joshua D Milner Jeffrey R Stinson, Elisa Ruffo, Batsukh Dorjbal, Swadhinya Arjunaraja, Kelsey Voss, Andrew L Snow Jordan K Abbott, Pia J Hauk, Paul R Reynolds, Erwin W Gelfand Elisa Ruffo Salomé Glauzy, Natsuko Yamakawa, Eric Meffre Jennifer Stoddard, Julie Niemela, Sergio D Rosenzweig Yu Zhang, Helen F Matthews Joshua J McElwee Nina Jones Alejandro Palma, Matías Oleastro, Emma Prieto, Andrea R Bernasconi, Geronimo Dubra, Silvia Danielian, Jonathan Zaiat, Marcelo A Marti Brian Kim Megan A Cooper Neil Romberg | 2017 | 现代生物医学进展2017，17，27： | 3 |
| 10 | Diagnostic accuracy of tests for Helicobacter pylori in an Alaska Native population显示文摘AIM:To evaluate the accuracy of two non-invasivetests in a population of Alaska Native persons. Highrates of Helico bacter pylori(H. pylori) infection,H. pylori treatment failure,and gastric cancer in this population necessitate documentation of infection status atmultiple time points over a patient's life.METHODS:In 280 patients undergoing endoscopy,H. pylori was diagnosed by culture,histology,rapidurease test,13C urea breath test(UBT) ,and immuno-globulin G antibodies to H. pylori in serum. The performances of 13C-UBT and antibody test were compared to a gold standard defined by a positive H. pylori testby culture or,in case of a negative culture result,bypositive histology and a positive rapid urease test.RESULTS:The sensitivity and specificity of the 13C-UBT were 93% and 88%,respectively,relative to thegold standard. The antibody test had an equivalents ensitivity of 93% with a reduced specificity of 68%.The false positive results for the antibody test were as-sociated with previous treatment for an H. pylori infection [relative risk(RR) = 2.8]. High levels of antibodiesto H. pylori were associated with chronic gastritis and male gender,while high scores in the 13C-UBT testwere associated with older age and with the H. pyloribacteria load on histological examination(RR = 4.4) .CONCLUSION:The 13C-UBT out performed the anti-body test for H. pylori and could be used when a non-invasive test is clinically necessary to document treatment out come or when monitoring for reinfection. | Dana L Bruden Michael G Bruce Karen M Miernyk Julie Morris Debby Hurlburt Thomas W Hennessy Helen Peters Frank Sacco Alan J Parkinson Brian J McMahon | 2011 | World Journal of Gastroenterology2011，17，42： | 3 |
| 11 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | 2005 (9472)2005，，9472： | 2 |
| 12 | Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial显示文摘 | Pierre J Guillou Philip Quirke Helen Thorpe Joanne Walker David G Jayne Adrian MH Smith Richard M Heath Julia M Brown | 2005 | The Lancet2005，，9472： | 2 |
| 13 | Adsorption of copper (Ⅱ) and chromium (Ⅲ) ions onto amidoximated cellulose 显示文摘 | RIMA S HELENE G MICHELE P R | 2000 | Journal of Applied Polymer Science2000，75，13： | 1 |
| 14 | Corporate global culture as competitive advantage:learning from Germany and Japan in Alabama and Austria显示文摘 | HELEN J M | 2002 | Journal of Business2002，37，： | 1 |
| 15 | Prognosis value of radionu clide angiography in patients with right ventricular arrhythmias 显示文摘 | Dominique LG Helene G Raphael P | 2001 | Circ2001，103，15： | 1 |
| 16 | Cryopreserved-thawedembryo transfer in natural or down-regulated hormonallycontrolled cycles: aretrospectivestudy 显示文摘 | Tarek G Luciano N Helen H | 2006 | Fertil Steril2006，85，3： | 1 |
| 17 | Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma显示文摘 | Deirdre T Helen C Andrew G J | 2008 | Vaccine2008，26，35： | 1 |
| 18 | Current status of dry and quasi-dry processes for pollutant separation from waste incineration plants and power stations 显示文摘 | Mayer-Schwinning G Helen H | 1995 | Environment Solution1995，32，2： | 1 |
| 19 | Increased nuclear factor кB activation critically ill patients who die 显示文摘 | Ross L P Helen F G Jatinde K D | 2000 | Crit Care Med2000，28，： | 1 |
| 20 | Diabetes and advanced glycoxidation end products显示文摘 | Huebschmann G Regensteiner JG Helen V | 2006 | Diabet Care2006，29，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员